Reed Elsevier Group

March 29, 2005 11:00 ET

Elsevier MDL to Build New Electronic Lab Notebook for Life Sciences Research; MDL Isentris Technology Will Enable a New-Generation ELN That Aids R&D




MARCH 29, 2005 - 11:00 ET

Elsevier MDL to Build New Electronic Lab Notebook for
Life Sciences Research; MDL Isentris Technology Will
Enable a New-Generation ELN That Aids R&D

SAN LEANDRO, Calif.--(CCNMatthews - Mar 29, 2005) -

In response to industry and customer demand, Elsevier MDL has launched a
dedicated, phased program to build a robust, scalable,
enterprise-strength electronic laboratory notebook (ELN) for the life
sciences, built on MDL® Isentris® technology, for delivery in 2006.

"Elsevier MDL pioneered the first all-electronic laboratory notebook
over a decade ago and is today a leader in the development and
deployment of advanced ELN systems that combine the best features of
paper notebooks with robust electronic data handling capabilities," said
Elsevier MDL CEO Lars Barfod. "A new generation ELN that satisfies both
intellectual property and regulatory requirements is a unifying
application that will significantly reduce cycle time in
biopharmaceutical R&D."

Biopharma researchers engaged in experiment planning and data
capture/analysis supporting parallel synthesis, single- and multi-step
reactions and other complex processes are increasingly demanding an
electronic laboratory data capture, report generation, auditing,
tracking and storage solution that supports FDA- and OSHA-mandated Good
Manufacturing and Good Laboratory Practices, as well as 21 CFR Part 11
compliance. An integrated ELN system offers many productivity benefits:
streamlining workflows, automating repetitive tasks, documenting
discovery history for patent disclosure and defense and leveraging past
work. In addition, an integrated ELN ensures that information captured
in the system can benefit everyone in an R&D organization.

The open, scalable, extensible and proven MDL Isentris discovery
informatics platform offers the technology framework for building and
delivering a variety of ELNs. The first ELN release will address the
needs of discovery scientists, particularly in organic synthetic
chemistry, with a scope encompassing authentication, sign/witness,
audit, notebook record repository and reporting services with extensive
workflow customization capabilities. The first release will integrate
with MDL structure and reaction registration services, with the MDL®
Discovery Logistics materials management solution, and with both
Elsevier MDL and proprietary customer content. The first ELN will also
support collaborative searching of hosted content via the
DiscoveryGate® platform for scientific research. Subsequent ELN
releases will provide additional functionality supporting development
chemistry and biology workflows.

Elsevier MDL offers extensive experience in developing and delivering
ELN consulting applications, deep domain knowledge in chemistry and
biology workflows, a large existing biopharmaceutical customer base and
a corporate commitment to the pharmaceutical and wider scientific
marketplaces. For all of these reasons, Elsevier MDL is positioned to
exert a significant presence in the rapidly emerging ELN market.

With the release of the new ELN, current Elsevier MDL customers using
the existing MDL® Elan application will have the option to implement a
modern, new generation ELN solution.

Elsevier MDL is interested in working with customers to identify
specific requirements for the new-generation ELN. Research organizations
with an interest in defining and validating these requirements should
contact an Elsevier MDL Account Manager.

About Elsevier MDL

Elsevier MDL provides informatics, database and workflow solutions that
accelerate the discovery and development of successful new drugs by
improving the speed and quality of scientists' decision making.
Commercial, academic and government life sciences researchers around the
world depend on Elsevier MDL for innovative and reliable discovery
informatics software solutions and services augmented by 400 Elsevier
chemistry and life sciences journals and related products. For more
information, visit

Elsevier is a world-leading publisher of scientific, technical and
medical information products and services. Working in partnership with
the global science and health communities, the company publishes more
than 1,800 journals and 2,200 new books per year, in addition to
offering a suite of innovative electronic products and online reference
works. For more information, visit

Elsevier is part of Reed Elsevier Group plc, a world-leading publisher
and information provider. Reed Elsevier's ticker symbols are REN
(Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York
Stock Exchange). For more information, visit

MDL, Isentris and DiscoveryGate are registered trademarks of MDL
Information Systems, Inc. ('Elsevier MDL') in the United States and/or
other countries. All rights reserved.


Contact Information

    Elsevier MDL
    Dr. Phil McHale, 510-357-2222 ext. 3541